Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of H7N9 LAIV in Healthy Adults
NCT02480101Phase 1Completed
- Sponsor
- Smorodintsev Research Institute of Influenza
- Start
- Oct 2014
- Primary completion
- Dec 2014
- Modality
- Live Attenuated Vaccines
01
Overview
Phase 1, randomised, double-blind trial comparing H7N9 LAIV with Placebo (2 arms). Primary endpoints: Immediate reactions at 2 hours, Solicited adverse events at 6 days and 2 more. Started Oct 2014; status: completed.
02
Drugs
H7N9 live attenuated influenza vaccine
Beyond the preview
Go deeper on NCT02480101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02480101.